# Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

> **NCT07062627** · PHASE2 · RECRUITING · sponsor: **Hyungwoo Cho** · enrollment: 12 (estimated)

## Conditions studied

- Primary CNS Lymphoma (PCNSL)
- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **GENETIC:** Anbal-cel

## Key facts

- **NCT ID:** NCT07062627
- **Lead sponsor:** Hyungwoo Cho
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07062627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07062627, "Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07062627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*